Emergent BioSolutions Announces Board Member Retirement
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Emergent Biosolutions ( (EBS) ).
Emergent BioSolutions announced the retirement of Dr. Louis W. Sullivan from its Board of Directors, effective November 14, 2025, after 19 years of service. Dr. Sullivan, who has been a key advisor and leader, contributed significantly to the company’s mission and strategic decisions, including its ongoing multi-year transformation.
The most recent analyst rating on (EBS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.
Spark’s Take on EBS Stock
According to Spark, TipRanks’ AI Analyst, EBS is a Outperform.
Emergent Biosolutions’ overall stock score is driven by strong earnings call results and positive technical analysis. The company has shown resilience in profitability and cash flow management, despite revenue challenges. Valuation metrics suggest the stock is undervalued, providing potential for future growth. However, high leverage and revenue decline remain concerns that need addressing.
To see Spark’s full report on EBS stock, click here.
More about Emergent Biosolutions
Emergent BioSolutions is a company focused on delivering protective and life-saving solutions for health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies. With over 25 years of experience, the company is dedicated to preparing those responsible for protecting public health.
Average Trading Volume: 1,135,877
Technical Sentiment Signal: Buy
Current Market Cap: $577.2M
Find detailed analytics on EBS stock on TipRanks’ Stock Analysis page.
